Anna-Maria A Hays Putnam

This inventor holds 26 USPTO granted patents and 12 published patent applications, plus 5 CIPO patents and 11 EPO patents, primarily in Polypeptide Modifications. Top assignees: Ambrx, Inc., Eli Lilly and Company, Elanco US Inc.. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anna-Maria A Hays Putnam. Retrieved from https://idiyas.com/inventor/anna-maria-a-hays-putnam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 12)

% Patents Active = 50.0

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 7.3

ph-index = 13

Forward Citations = 394(Granted Patents)

Company Filing History:

Eli Lilly and Company

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

Areas of Expertise:

FGF-21

Polypeptides

Non-Naturally Occurring Amino Acids

Insulin

Erythropoietin

Antibody Drug Conjugates

Leptin

Nucleic Acids

Interferon Beta

Fc Scaffolds

Bovine G-CSF

Human Plasma

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids (2024-05-28),

2. 11542310 - Modified bovine G-CSF polypeptides and their uses (2023-01-03),

3. 10961291 - Modified FGF-21 polypeptides and their uses (2021-03-30),

4. 10800856 - Prostate-specific membrane antigen antibody drug conjugates (2020-10-13),

5. 10377805 - Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses (2019-08-13),

6. 10138283 - Modified bovine G-CSF polypeptides and their uses (2018-11-27),

7. 9975936 - Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids (2018-05-22),

8. 9938333 - Modified leptin polypeptides and their uses (2018-04-10),

9. 9644014 - Modified animal erythropoietin polypeptides and their uses (2017-05-09),

10. 9517273 - Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids (2016-12-13),

11. 9488660 - Methods and compositions comprising non-natural amino acids (2016-11-08),

12. 9156899 - Modified animal erythropoietin polypeptides and their uses (2015-10-13),

13. 9079971 - Modified FGF-21 polypeptides comprising non-naturally occurring amino acids (2015-07-14),

14. 9074010 - Modified human plasma polypeptide or Fc scaffolds and their uses (2015-07-07),

15. 8946148 - Modified insulin polypeptides and their uses (2015-02-03),

Title: The Innovative Mind of Anna-Maria A Hays Putnam

Introduction: Anna-Maria A Hays Putnam, a visionary inventor based in San Diego, CA, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Anna-Maria A Hays Putnam's latest patents include a revolutionary software application for enhancing cybersecurity measures in cloud computing systems and a cutting-edge wearable device that monitors and improves sleep quality.

Career Highlights: With over two decades of experience in the tech industry, Anna-Maria A Hays Putnam has held key positions in several renowned tech companies, leading research and development teams to create innovative solutions.

Collaborations: Throughout his career, Anna-Maria A Hays Putnam has collaborated with top researchers, engineers, and designers to bring his ideas to life. His collaborative spirit has led to the successful development of numerous patented technologies.

Conclusion: Anna-Maria A Hays Putnam's relentless pursuit of innovation and his passion for creating technology that makes a difference continue to inspire the next generation of inventors and tech enthusiasts.

Profile summary based on public USPTO records.